New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression

Author's Avatar
May 05, 2018
Article's Main Image

- Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both the control and placebo groups

- Study in elderly patients is the first large clinical trial in treatment-resistant depression in this population

- Results demonstrate the potential of esketamine nasal spray to address a significant unmet need for the more than 30 percent of people suffering from major depressive disorder who do not respond to two or more currently available antidepressants(1)

PR Newswire